Adeno-associated virus (AAV) has become a leading gene transfer vector for striated muscles. However, the AAV vectors also exhibit broad tropisms after systemic delivery. In an attempt to improve muscle tropism, we inserted a 7-amino-acid (ASSLNIA) muscle-targeting peptide (MTP) in the capsids of AAV2 at residue 587 or 588, generating AAV 587 MTP and AAV 588 MTP. In vitro studies showed that both viruses diminished their infectivity on non-muscle cell lines as well as on un-differentiated myoblasts; however, preserved or enhanced their infectivity on differentiated myotubes. AAV 587 MTP, but not AAV 588 MTP, also abolished its heparin-binding capacity and infected myotubes in a heparin-independent manner. Furthermore, in vivo studies by intravenous vector administration in mice showed that AAV 587 MTP enhanced its tropism to various muscles and particularly to the heart (24.3-fold of unmodified AAV2), whereas reduced its tropism to the non-muscle tissues such as the liver, lungs, spleen and so on. This alteration of tissue tropism is not simply because of the loss of heparin-binding, as a mutant AAV2 (AAVHBSMut) containing heparin-binding site mutations lost infectivity on both non-muscle and muscle cells. Furthermore, free MTP peptide, but not the scrambled control peptide, competitively inhibited AAV 587 MTP infection on myotubes. These results suggest that AAV2 could be retargeted to the striated muscles by a MTP inserted after residue 587 of the capsids. This proof of principle study showed first evidence of peptide-directed muscle targeting on systemic administration of AAV vectors.
Introduction
Diseases of the heart and skeletal muscles affect adults and children worldwide. Gene therapy represents an attractive strategy for a variety of muscle diseases such as muscular dystrophies and heart failure.
1,2 Gene transfer vectors, including non-viral and viral vectors, have been shown to accomplish gene delivery to local muscle and heart tissue by direct intramuscular (i.m.) injection or by local vessel perfusion. 3, 4 The simplest approach of gene therapy is the injection of naked plasmid DNA encoding the therapeutic gene into muscle. 5 Although plasmid DNA delivery could achieve long-term gene expression, 6 the delivery efficiency of naked plasmid is low after i.m. injection. Viral vectors, especially the adeno-associated virus (AAV) vectors, 7 offer effective alternative approaches for muscle-directed gene transfer. To functionally correct disorders affecting the heart and skeletal muscles, delivery of gene vectors to a majority of the diseased cells is required. After direct i.m. injection, AAV vectors can readily saturate individual muscles around the injection sites. 8 Gene transfer to large groups of muscles by multiple i.m. injections is feasible, 9 but ineffective and impractical for muscular dystrophies that affect muscles body-wide. Systemic delivery of AAV vectors to the muscle and heart has been achieved by a single intravenous (i.v.) or intraperitoneal injection of AAV vectors. 10, 11 However, the AAV vectors also non-specifically infect a variety of nonmuscle tissues. As a result, targeting the AAV vectors to the muscle after systemic delivery is a highly desirable and yet challenging task for muscle-directed gene therapy.
One of the approaches of targeting AAV to the muscle is to alter its native interactions with the cellular receptors and retarget the virus through a different binding ligand to the muscle. Among the currently used AAV serotypes, AAV2 is the best-characterized serotype for its viral-cellular interactions. It is also the bestdocumented AAV vector in pre-clinical studies and clinical trials in the past 20 years. 12 Therefore, AAV2 can serve as a good candidate for genetic engineering of detargeting and retargeting. AAV2 uses cell membraneassociated heparan sulfate proteoglycan as its primary binding receptor and its transduction can be efficiently competed by free heparin. 13 In addition, AAV2 utilizes a number of membrane proteins such as aVb5 integrin, 14 fibroblast growth factor receptor-1, 15 hepatocyte growth factor receptor (c-Met) 16 and a5b1 integrin 17 as its co-receptors for cell entry. As AAV tropism is determined by a specific interaction between viral capsids and host cellular receptors, [13] [14] [15] [16] [17] modification of capsid proteins has emerged as a means to alter native vector tropism. In addition, incorporation of targeting peptides selected by either phage display 18 or AAV display 19 on the surface of AAV capsids has been used to target the vector to specific cell types. [20] [21] [22] [23] [24] [25] Earlier, insertion of an angiogenic vascular-targeting motif NGR on AAV2 capsid successfully redirected vector tropism to cells expressing the NGR receptor CD13 that is presented in angiogenic vasculature and in many tumor cell lines. 22 Similarly, the incorporation of endothelium-specific peptide SIGYPLP into the AAV2 capsid at position 587 displayed an altered tropism towards human vascular endothelial cells. The infection happened to be independent of heparan sulfate proteoglycan binding. 23 A recent study also showed that the insertion of MTPFPTSNEANL peptide into AAV2 capsid after amino acid 587 enhanced gene delivery of AAV vectors into a specific vascular site in vivo and these vectors transduced the vena cava independently of heparan sulfate proteoglycan binding. 24 Moreover, Work et al. 25 identified peptides homing to the lung and brain by in vivo phage display from rats and they showed that the isolated targeting peptides retargeted AAV vectors to the expected organs in a preferential manner. However, no efforts have been reported on systemic re-targeting of AAV to the muscles, either cardiac and/or skeletal.
In this report, we describe the construction and evaluation of AAV2 vectors genetically modified with a muscle-targeting peptide (MTP), which was originally isolated by phage display in differentiated muscle cells in vitro and muscle tissue in vivo. 26, 27 The MTP-modified AAV2 showed improved tropisms to the striated muscles, and could efficiently and selectively infect differentiated muscle cells in vitro and skeletal and cardiac muscles in vivo.
Results

Genetic modification of AAV2 capsids with a MTP
Ligand insertion at amino acid residues 587 and 588 of AAV2 capsids can be well tolerated. 19, [22] [23] [24] [25] We therefore genetically inserted the MTP ASSLNIA 26, 27 after 587 or 588 site of the AAV2 capsid gene, resulting in two MTPmodified AAV2 capsid mutants: AAV 587 MTP and AAV 588 MTP (Figure 1a) . The MTP insertion after 587 of the AAV2 capsid disrupted the heparin-binding motif and is expected to lose its heparin-binding capability, which is the primary mechanism of AAV2 cell binding and entry. 13 In addition, we have generated a third mutant: AAVHBSMut, which had all three arginines mutated (R484E, R585A and R588A) at the heparinbinding site of the AAV2 capsids ( Figure 1a) . But further insertion of MTP after 587 of AAVHBSMut caused failure of AAV vector packaging (data not shown). The above three mutant AAV capsids were used to package AAV vectors containing either green fluorescent protein (GFP) or luciferase reporter genes. DNA dot-blot assays showed that all three mutant AAVs could yield AAV vector titers comparable to that of the unmodified AAV2 (data not shown). Furthermore, western analysis using the same quantity of viral particles (viral genomes (v.g.)) of the three mutants and the unmodified AAV2 did not reveal abnormal quantity or stoichiometry of capsid proteins, VP1, VP2 and VP3 (Figure 1b) , suggesting that the formation of the viral particles and the DNApackaging capacity were not impaired by these mutations.
MTP re-targets AAV2 to myotubes and abolishes infectivity to non-muscle cells in vitro
We next examined the effects of MTP insertion on the infectivity of AAV2 in vitro on differentiated muscle cells, the myotubes. As the ASSLNIA peptide was originally isolated by phage-display selection in murine C2C12 myotubes 26 that express many of the proteins presented in skeletal muscles, C2C12 myotubes were used to validate the muscle-targeting efficiencies of peptidemodified AAV vectors in vitro. First, a luciferase (Luc) reporter vector packaged by AAV 587 MTP, AAV 588 MTP, AAVHBSMut and unmodified AAV2 was used to infect differentiated C2C12 cells, which formed myotubes after differentiation. As shown in Figure 2a , both AAV 587 MTP and AAV 588 MTP were able to transduce C2C12 myotubes at similar levels as the unmodified AAV2 vector, although AAV 587 MTP was slightly lower and AAV 588 MTP was slightly higher (Figure 2a ). As expected, AAVHBSMut with triple mutations on the heparinbinding site dramatically abolished its transduction on C2C12 myotubes by more than 2600-fold (Figure 2a) . To confirm the results obtained by the luciferase reporter vectors, we also used a GFP reporter vector packaged in the same viral capsids and tested again on differentiated C2C12 myotubes in a similar manner. Fluorescent microscopy showed green fluorescence on myotubes infected with unmodified AAV2, AAV 587 MTP and AAV 588 MTP, but not on myotubes infected with AAVHBSMut (Figure 2b) , consistent with the results from the luciferase reporter vectors. were separated on 10% sodium dodecyl sulfate-PAGE and analyzed by western blotting, using anti-AAV2 capsid guinea pig sera.
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To further evaluate the targeting specificity of peptidemodified vectors, undifferentiated C2C12 myoblasts were infected for 2 days with the luciferase vectors. AAV 587 MTP and AAV 588 MTP showed decreased transduction by 92.59 and 96.95% when compared with the unmodified AAV2, whereas AAVHBSMut had almost undetectable transduction in undifferentiated C2C12 cells (Table 1) . Similar experiments were also done using non-muscle cell lines including HepG2, a human hepatocellular carcinoma cell line, HeLa, a human cervix epitheloid carcinoma cell line, HEK 293, a human embryonic kidney cell line and U-87MG, a human glioblastoma tumor cell line (Table 1 ). All the three mutant AAVs showed dramatic decreases in transduction when compared with the unmodified AAV2, indicating that the insertion of MTP could diminish the native infectivity of AAV2 on the permissive non-muscle cells in vitro. 
AAV 587 MTP infection in myotubes is heparin-independent and MTP-dependent
To examine if the insertion of MTP peptide impaired heparin-binding capacity of the mutant AAVs, we carried out an in vitro heparin-binding assay. Three mutant AAV vectors and the unmodified AAV2 vector were loaded (5 Â 10 11 v.g. each) onto heparin columns for binding. After extensive wash, the bound AAVs were eluted by 1 M NaCl. Fractions from loading flowthrough, wash and elution were all collected for viral particle analyses. Viruses were monitored by DNA-dot blot using the cytomegalovirus (CMV) promoter probe ( Figure 3a ) and also by western blot using a guinea pig anti-AAV2 serum ( Figure 3b ). As expected, the unmodified AAV2 showed high affinity for the heparin column, and were only found in the elution fraction ( Figure 3a) . AAV 588 MTP also displayed similar heparin-binding ability to the unmodified AAV2. The majority of the AAV 588 MTP was found in the elution fraction with negligible amount in the wash fraction. In contrast, AAV 587 MTP viruses were substantially detected in the wash fraction as well as in the elution faction. As expected, AAVHBSMut was detected in the loading flow-through faction, and mostly in the wash fraction, but undetectable in the elution fraction. These results suggest that the loss of heparin-binding capacities is extensive for AAVHBSMut, substantial for AAV 587 MTP but minor for AAV 588 MTP.
Next, we carried out a competitive inhibition experiment with soluble heparin to see if the loss of heparin binding makes the viral infection in an heparan sulfate proteoglycan-independent manner. Differentiated C2C12 myotubes were infected with unmodified AAV2, AAV 587 MTP and AAV 588 MTP containing a luciferase report gene in the presence of soluble heparin, which is known to competitively inhibit AAV2 infection. 13 As expected, the transduction of AAV 587 MTP vector was not inhibited by heparin, whereas both unmodified AAV2 and AAV 588 MTP vectors significantly diminished their transduction efficiency by 72.03 and 42.25%, respectively, in the presence of heparin sulfate (Po0.05) (Figure 3c ).
Finally, we examined if infection of differentiated myotubes by AAV 587 MTP is mediated by the MTP peptide insertion on the capsids. Unmodified AAV2 and AAV 587 MTP were compared for their transduction efficiencies (luciferase reporter gene transfer) on C2C12 11 of unmodified or peptideinserted viruses were loaded onto a prepacked and equilibrated 1 ml heparin column. Viral particles that appeared in the flow-through, wash and elution fractions were then detected by DNA dot-blot with cytomegalovirus (CMV) probe. The fractions from the heparin-affinity column analysis were also analyzed by western blot using guinea pig anti-AAV2 serum. The positions of VP1, VP2 and VP3 are indicated. I, input; F, flow-through; W, wash step; E, elution. 
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C-Y Yu et al myotubes in the presence of the specific peptide (ASSLNIA), or a scrambled peptide (LISNSAA). Infection without any competing peptide was used as a positive control. As shown in Figure 3d , AAV 587 MTP transduction was significantly inhibited (47.30%) by 2 mg ml À1 free ASSLNIA peptide (Po0.05), but not by free LISNSAA. The inhibition of unmodified AAV2 by free ASSLNIA peptide was statistically insignificant when compared with the control without peptide (P40.3). These results suggest that the MTP could re-target AAV2 to differentiated myotubes.
MTP peptide enhances AAV 588 MTP infectivity to skeletal muscle after local i.m. injection
We next investigated if the MTP could enhance AAV2 infectivity to the skeletal muscles. Adult male Imprinting Control Region (ICR) mice (2 months of age, four mice in each group) were injected in the tibialis anterior muscle of the hind legs with luciferase vectors packaged in unmodified AAV, AAV 587 MTP and AAV 588 MTP (2.5 Â 10 10 v.g. each). The tibialis anterior muscles were collected at 4 weeks after i.m. injection of the vectors for luciferase activity assay. When compared with the control AAV2, AAV 587 MTP had a slightly lower luciferase gene expression, whereas AAV 588 MTP had a 3.2-fold increase (Figure 4 ). This result mirrors the luciferase activity profile obtained in the in vitro assay on differentiated myotubes (Figure 2 ), suggesting that AAV 587 MTP might primarily use the MTP for cell entry, whereas AAV 588 MTP might use a dual mechanism, both heparin binding and MTP.
MTP peptide retargets AAV 587 MTP to heart and muscle after systemic i.v. injection
We next investigated whether MTP could enhance the infectivity of AAV2 in vivo to the heart and skeletal muscles after systemic delivery by i.v. injection. Adult ICR mice (8-week-old) were administered with unmodified AAV2, AAV 587 MTP or AAV 588 MTP containing the CMV-luciferase reporter gene cassette through the tail vein at a dose of 9 Â 10 11 v.g each. At 4 weeks after i.v.
injection, luciferase reporter gene expression was analyzed in various tissues. AAV 587 MTP achieved higher luciferase gene expression than the unmodified AAV2, and surprisingly, AAV 588 MTP in various muscles and heart after systemic delivery. The luciferase activity of AAV 587 MTP in the heart was 24.3-fold of that of the unmodified AAV2, whereas the activity of AAV 588 MTP was only 1.82-fold of the unmodified AAV2 (Figure 5a) . In skeletal muscles, the luciferase activity of AAV 587 MTP was 2.18-fold of the AAV2 in the diaphragm and 2.85-fold in quadriceps (Figure 5b) . Moreover, the AAV 587 MTP showed reduced transduction in the liver, lungs, spleen, etc. than the unmodified AAV2 (Figure 5c ). In contrast, AAV 588 MTP showed reduced transduction in most tissues, muscle as well as non-muscle, after systemic delivery (Figures 5b and c) .
Quantitative PCR was also carried out on samples collected from AAV2-and AAV 587 MTP-treated mice for vector tissue distribution. The results showed that AAV 587 MTP vector DNA copy number in the heart increased by 6.6-fold when compared with the unmodified AAV2 (7.28±3.91 copies vs 0.96±0.45 copies per ng of tissue DNA, Po0.05) (Figure 6a ). The vector DNA copy numbers also increased in various skeletal muscles, including the diaphragm, upper limbs, quadriceps, gastrocnemius and tibialis anterior muscles when compared with the unmodified AAV2 vector (Figure 6a) . However, the vector DNA copy numbers of AAV 587 MTP in the liver was less than half (39.4%) of that of unmodified AAV2 (Figure 6b ). In addition, AAV 587 MTP also showed an approximately 10-fold lower vector DNA distribution in the lung and spleen (Figure 6b ). The realtime PCR results were essentially consistent with the luciferase gene expression profiles, suggesting that MTP could de-target AAV 587 MTP from non-muscle tissues and re-target it to the striated muscles including the heart and skeletal muscle after systemic delivery.
Discussion
A number of AAV serotype vectors are able to achieve systemic gene delivery into the heart and skeletal muscles, but also show strong tropisms to non-muscle tissues. 10, 11, 28, 29 Ideally, systemic delivery of therapeutic genes to striated muscles requires not only efficiency, but also tissue specificity. In an attempt to improve the muscle tropism of AAV vectors by ligand-directed gene delivery, we have genetically modified AAV2 capsid surface with an MTP, a small 7-mer peptide ASSL-NIA. 26, 27 On cultured cells in vitro, the insertion of MTP not only furnished AAV2 with infectivity to differentiated myotubes, but also ablated or impaired its infectivity to the otherwise permissive non-muscle cells. Furthermore, insertion of MTP at capsid position 588 was able to enhance AAV2 infectivity in vivo to the muscle myofibers by 3.2-fold after i.m. injection. On the otherhand, MTP at position 587 could re-target AAV2 to the heart (an increase of 23.3-fold), and at a less degree, to skeletal muscles after systemic injection. The above phenomena suggest that AAV 587 MTP may have improved capacity to cross the capillary blood vessel barrier in striated muscles, particularly in the heart. Although much room remains for further improvement and optimization, we believe that our results show the Muscle-targeting peptide re-targets AAV2 C-Y Yu et al first example of a ligand-directed targeting of AAV vectors to the striated muscle tissues. As AAV2 is not a robust virus for either direct local or systemic gene delivery into the heart and muscle, the incorporation of the MTP onto the surface of capsids of more powerful AAV serotype capsids such as AAV7, 8 and 9, which are efficient in crossing the blood vessel barrier to reach muscle myofibers in vivo, could render them more effective in targeting muscles in vivo for systemic gene delivery.
In this study, we chose to modify serotype AAV2 with the MTP, primarily on the basis of the wealth of information on AAV2 viral capsid structure and functional relationship. Although AAV2 is not the best vector for gene delivery to the muscle, it has been extensively used in mutagenesis studies including point mutations, linker insertions and peptide display on its capsids. [19] [20] [21] [22] [23] [24] [25] 30 Peptide insertions at amino acid residues 587 and 588 are well tolerated because the loop structure is exposed on the surface of the capsids. 19, [22] [23] [24] [25] 30 Insertion at 587 also interferes and abolishes viral particle binding to heparan sulfate proteoglycans, which are ubiquitous on cell surface of almost all tissues 31 as a primary receptor for AAV2 attachment and cell entry. 13 Ablation of heparin binding should facilitate tissue-specific targeting. Although both AAV 587 MTP and AAV 588 MTP had the same MTP insertion, AAV 587 MTP largely lost its heparinbinding capacity, whereas AAV 588 MTP had a minor loss. As such, AAV 587 MTP exhibited better muscle targeting in vivo after systemic delivery, whereas AAV 588 MTP might use a dual mechanism through both heparin and MTP for cell binding and entry. It is important to note that the loss of heparin binding alone could not account for the improved muscle targeting of AAV 587 MTP, because a heparin-binding deficient mutant AAV2 (AAVHBSMut, R484-E, R585-A and R588-A) not only failed to achieve significant infection on cultured myotubes (Figure 2 ), but also failed to achieve luciferase reporter gene expression higher than basal levels in all the organs and tissues tested after systemic tail vein injection (data not shown). Furthermore, free MTP peptide, but not the scrambled peptide, on myotube culture could inhibit the transduction of AAV 587 MTP but not the unmodified AAV2, suggesting that the MTP is responsible in part for retargeting the AAV2 to the striated muscle tissues, particularly the heart.
In this study, we have examined two MTP-modified AAV2 capsids on cultured cells in vitro and in mice in vivo by direct vector injection. In the in vitro experiments, both AAV 587 MTP and AAV 588 MTP dramatically lost their infectivities (B100-fold) to all the cell types tested including the undifferentiated myoblast 
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It suggested that the MTP insertion played a major role in de-targeting AAV2 from non-muscle cells and re-targeting it to myotubes in vitro. However, the in vivo de-targeting and re-targeting results by the MTP-modified AAV2 were much less impressive than the results obtained in vitro. These discrepancies could be attributed primarily to the profound in vitro and in vivo differences in the environment throughout the process of AAV infection. It is well documented that AAV2 vectors are robust in vitro but less efficient in vivo, whereas numerous new AAV serotypes are exactly the opposite. The viruses might favor different receptors or coreceptors in vivo. Furthermore, the serum proteins and a barrage of different cell types in vivo could also alter the behavior of the vectors. Another reason could be the high complexity and variability of in vivo experiments. In our study, reporter gene expression in some muscle groups showed statistical differences between the wt AAV2 and MTP-modified AAV2, whereas other groups did not. We have also observed discrepancies between reporter gene expression and vector DNA copy numbers in some tissues, which again could reflect the complex situations in vivo. For example, it was shown that AAV2 and AAV8 had similar vector copy numbers in the liver shortly after i.v. vector delivery. However, AAV8 achieved dramatically high levels of gene expression because of more efficient intracellular trafficking and uncoating of the viral particles. 32 Therefore, direct in vivo screening and evaluation of new vectors should be a more reliable and preferred method.
Finally, we believe that minor differences on MTP insertion sites (587 vs 588) and the linker sequences flanking the MTP made a significant difference on the behavior between AAV 587 MTP and AAV 588 MTP. These differences could not be simply explained by the alteration of heparin binding. It is conceivable to see a near complete loss of infectivity of AAV 587 MTP on the permissive non-muscle cell lines for AAV2 because of the loss of heparin binding. But AAV 588 MTP also showed a near complete loss of infectivity on those cells, although its heparin-binding motif RXXR (X is any amino acid) is still intact. 33 Again unexpectedly, AAV 588 MTP was significantly more resistant than AAV 587 MTP to anti-AAV2 antibody neutralization using anti-sera from guinea pig, mouse and pooled human IVIG (data not shown), despite the presence of intact heparin-binding motif. An earlier report showed that linker sequences flanking the peptide insertion could significantly influence the configuration and display of the engineered peptide epitope. 34 Insertion of an integrin-specific peptide ligand (L14) at residue 587 of AAV2 capsid enabled the vector to escape antibody neutralization. 34 However, it was not true for AAV 587 MTP, which was as sensitive to human IVIG as the unmodified AAV2. Molecular modeling [35] [36] [37] of the putative three-dimensional structures of those capsids (data not shown) revealed that the loop containing the heparin-binding RXXR motif is missing on AAV 587 MTP, but still exists on AAV 588 MTP, supporting the in vitro heparin binding and inhibition data (Figure 3 ). On the other hand, the MTP loop is extended and protruding on AAV 587 MTP, but takes a fold-back configuration on AAV 588 MTP. This may make the MTP on AAV 588 MTP less effective for muscle targeting, but more effective on stereotactic blockade of neutralizing antibody binding to key components on AAV2. Thus, different linker contexts could assign different properties on the displayed peptide. It also echoes an earlier study that showed that the choices of linker sequences could make a big difference on AAV2 targeting and resistance to neutralizing antibodies, 30 a very important issue for in vivo gene delivery with AAV vectors in human patients.
38,39
Materials and methods
Cell culture
C2C12 murine myoblasts (ATCC (American Type Culture Collection), Rockville, MD, USA), human hepatocellular carcinoma HepG2 cells, human cervical carcinoma HeLa cells, human embryonic kidney 293 cells (HEK 293 cells) and human glioblastoma tumor U-87MG cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum. To induce the differentiation of C2C12 myoblasts into myotubes, the cells were switched from growth medium (DMEM with 10% fetal bovine serum) to differentiation medium (DMEM with 2% horse serum) and were incubated in differentiation medium for up to 9 days. After 4 days of differentiation, the C2C12 myotubes were fully formed. 
Plasmid construction
The plasmid pBSKS-AAV2Cap containing AAV2 cap gene was used as the template for the construction of all modified capsids by using PCR. The mutations of heparin-binding sites on AAV2 capsid were introduced by the mutagenic primers, which contain the desired mutation. For the peptide-modified capsids, we designed the primers encoding amino acids ASSLNIA flanked by peptide linker. This muscle-specific peptide (ASSLNIA) was then inserted into the site after residue 587 or residue 588 of AAV2 capsid by PCR. The synthesized PCR products were digested with DpnI endonuclease to eliminate the parental plasmid template and further added phosphates at 5 0 of oligonucleotides by T4 polynucleotide kinase (New England BioLabs, Ipswich, MA, USA) to allow subsequent ligation. 40 by EcoRV and XcmI.
AAV vector production and evaluation of AAV titers
To produce AAV virus, the three-plasmid cotransfection method was applied. 41 The plasmids used in transfection were the following: (i) AAV-CMV-Luc plasmid with the luciferase (Luc) gene driven by the CMV promoter, or AAV-CB-EGFP plasmid with the enhanced GFP (EGFP) gene controlled by the CB promoter (CMV enhancer/ chicken beta-actin promoter). Both plasmids carry the promoter-driven transgene flanked by AAV inverted terminal repeats; (ii) the pXX6 plasmid, which contains the helper genes from adenovirus and (iii) the modified pXX2 plasmid, which supplies AAV2 rep protein and modified capsid protein. As a control, wild-type AAV capsid was also prepared with unmodified pXX2 plasmid. The vector production and purification were carried out according to previously published method with two rounds of CsCl centrifugation. 41 AAV genomic titers were determined by DNA dot-blot assay. Briefly, 2 ml of the purified AAV stock was digested with DNase I (10 mg ml
À1
) in DMEM at 37 1C for 1 h and then 200 ml of 2 Â proteinase K buffer (20 mM Tris.Cl pH 8.0, 20 mM EDTA (ethylenediaminetetraacetic acid) pH 8.0 and 1% sodium dodecyl sulfate) was added. Next, proteinase K was added to reactions at a final concentration of 1 mg ml À1 and the samples were incubated at 55 1C for 1 h. Viral DNA was precipitated by ethanol and the DNA pellet was dissolved in an alkaline buffer (0.4 M NaOH, 10 mM EDTA pH 8.0). DNA samples were applied to Nylon membranes and probed with a horseradishperoxidase-labeled CMV or EGFP probe. Signals were detected by the North2South chemiluminescence kit (Pierce, Rockford, IL, USA). To detect if these mutant virions were composed of three capsid proteins, 2 Â 10 10 viral particles of unmodified or modified AAV-CMV-Luc virus were subjected to Western blotting with anti-AAV2 capsid guinea pig sera (purchased from ATCC).
In vitro transduction assay C2C12 myotubes were grown in 24-well plates and infected with AAV-CMV-Luc vectors at 2 Â 10 10 genomic particles per well and continued to incubate at 37 1C for 6 days. Then, myotubes were lysed for luciferase assay. In addition, the C2C12 myotubes were transduced with AAV-CB-EGFP at 1 Â 10 10 genomic particles per well. EGFP expression was observed under a Nikon TE-300 inverted fluorescent microscope (Nikon, Burlingame, CA, USA). Images were taken at Â 100 magnification at 72 h after infection.
For transduction in undifferentiated myoblasts and non-muscle cell lines, the cells were seeded in 12-well plate at the following cell densities per well: C2C12 at 2 Â 10 
Determination of AAV heparin binding
In heparin column chromatography, 5 Â 10 11 genomic particles of AAV-CMV-Luc were suspended in 0.5 ml of viral suspension buffer (50 mM NaH2PO4, 2 mM MgCl, 2.5 mM KCl, 50 mM Hepes, 150 mM NaCl, pH 8.0) and were then loaded onto a 1-ml HiTrap heparin column (Amersham Bioscience, Piscataway, NJ, USA) pre-equilibrated with 0.15 M NaCl and 50 mM Tris at pH 7.5. The column was further washed twice with 5 ml of binding buffer (10 mM NaH 2 PO 4 pH 7.0) and eluted twice with 5 ml of elution buffer (10 mM NaH 2 PO 4 , 1 M NaCl pH 7.0). The flow-through, wash and elution fractions were collected. 20 ml of each fraction was analyzed by DNA dot-blot assay with a CMV probe and was also subjected to western blotting with guinea pig anti-AAV2 capsid sera. Heparin dependence was verified by estimating viruses present in wash or elution fraction. For in vitro heparin competition assay, a total of 2 Â 10 10 genomic particles of AAV-CMV-Luc vectors were first incubated with or without 30 mg ml À1 heparin (from porcine intestinal mucosa; Sigma, St Louis, MO, USA) in DMEM containing 2% horse serum for 1 h at 37 1C. AAV alone or AAV-heparin mixture was added into C2C12 myotubes for 72 h. Cells were next given fresh DMEM with 2% horse serum and were subsequently incubated at 37 1C for 6 days. The infected myotubes
Muscle-targeting peptide re-targets AAV2 C-Y Yu et al were then harvested for the luciferase assay. The competitive blocking experiment by the synthetic peptides was carried out on C2C12 myotubes. AAV-CMV-Luc and C2C12 myotubes were preincubated with 2 mg ml À1 of the synthetic muscle-specific peptide (NH2-ASSLNIA-CONH2) or the scrambled peptide (NH2-LISNSAA-CONH2) as control at 37 1C for an hour. Then, AAV vectors were added onto C2C12 myotubes for 24 h. C2C12 myotubes were washed and changed with fresh DMEM containing 2% horse serum. After 96 h of continuous incubation, the cells were harvested and analyzed by luciferase assay.
Vector biodistribution studies in vivo
Eight-week-old adult male ICR-CD1 mice (4-6 per group) were injected intravenously through tail vein with a viral solution containing 9 Â 10 11 genomic particles of AAV-CMV-Luc. After 4 weeks, the mice were killed and representative organs (brain, heart, liver, skeletal muscles, kidney, testis, and spleen) were harvested for luciferase assay. Luciferase activity was expressed as RLU per mg protein. Genomic DNA was extracted from organs using DNeasy kit (Qiagen Inc., Valencia, CA, USA). Relative numbers of vector genome were determined using real-time PCR. A luciferase DNA standard curve was generated from serial dilutions of the pAAV CMV-Luc plasmid by use of SYBR green with 100 pmol ml À1 sense 5 0 -GACGCCAAAAACATAAAGA AAG-3 0 and antisense 5 0 -AGGAACCAGGGCGTATCT CT-3 0 Luc primers. A total of 200 ng of genomic DNA was used for PCR amplification and the PCR products were quantified using TaqMan data analysis software (Applied Biosystems, Foster City, CA, USA). All data were expressed as vector copies per ng genomic DNA. The following PCR reaction conditions were used: denaturation, 95 1C for 2 min; 40 cycles of amplification, 95 1C for 15 s, 60 1C for 1 min.
Statistical analysis
In vitro data were tested by unpaired Student's t-test with one-or two-tailed test. In vivo data were analyzed using the non-parametric Mann-Whitney U-test. Data were considered significant when Po0.05.
